Human PI3 activation kit by CRISPRa

CAT#: GA103535

PI3 CRISPRa kit - CRISPR gene activation of human peptidase inhibitor 3



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (2)
PI3 Antibody - N-terminal region
    • 100 ul

CNY 5,250.00


Lenti ORF particles, PI3 (Myc-DDK tagged) - Human peptidase inhibitor 3, skin-derived (PI3), 200ul, >10^7 TU/mL
    • 200 ul

CNY 7,410.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol PI3
Locus ID 5266
Kit Components

GA103535G1, PI3 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA103535G2, PI3 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA103535G3, PI3 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_002638
Synonyms cementoin; ESI; SKALP; WAP3; WFDC14
Summary This gene encodes an elastase-specific inhibitor that functions as an antimicrobial peptide against Gram-positive and Gram-negative bacteria, and fungal pathogens. The protein contains a WAP-type four-disulfide core (WFDC) domain, and is thus a member of the WFDC domain family. Most WFDC gene members are localized to chromosome 20q12-q13 in two clusters: centromeric and telomeric. This gene belongs to the centromeric cluster. Expression of this gene is upgulated by bacterial lipopolysaccharides and cytokines. [provided by RefSeq, Oct 2014]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...